Western Black Rhino Of Africa Officially Extinct, Conservation Group Announces

GENEVA — The Western Black Rhino of Africa has been declared officially extinct, and two other subspecies of rhinoceros are close to meeting the same fate, a leading conservation group said Thursday.

The International Union for Conservation of Nature said a recent reassessment of the Western Black Rhino had led it to declare the species extinct, adding that the Northern White Rhino of central Africa is now “possibly extinct” in the wild and the Javan Rhino is “probably extinct” in Vietnam, after poachers killed the last animal there in 2010.

A small but declining population of the Javan Rhino survives on the Indonesian island of Java, it added.

“A lack of political support and willpower for conservation efforts in many rhino habitats, international organized crime groups targeting rhinos and increasing illegal demand for rhino horns and commercial poaching are the main threats faced by rhinos,” the group said in a statement accompanying the latest update of its so-called Red List of endangered species.

About a quarter of all mammals are at risk of extinction, IUCN said, adding that some species have been brought back from the brink with successful conservation programs.

The Southern White Rhino numbered just 100 animals at the end of the 19th century, but has since flourished and now has a population of over 20,000.

The Przewalski’s Horse, a type of wild horse from Central Asia, has come back from extinction after a successful breeding program in captivity.

The Red List now contains almost 62,000 species of plants and animals, whose status is constantly monitored by conservationists.

Share

Hope for Malaria Vaccine After Blood Entry Route Discovered

By James Gallagher Health reporter, BBC News

The route all strains of the most deadly malaria parasite use to enter red blood cells has been identified by researchers at the Sanger Institute in Cambridge.

The scientists involved said the finding offered “great hope” for the development of a vaccine, which had the potential to be hugely effective.

Other experts said they were surprised and impressed.

Malaria affects 300 million people each year.

One million die, mostly children in sub-Saharan Africa.

There are many malaria parasites. Plasmodium falciparum is the most deadly and researchers at the Sanger Institute acknowledge it as a “very complex and cunning foe”.

It is exceptionally good at evading and bamboozling the immune system. Within five minutes of being bitten by a malaria-carrying mosquito, the parasite is already hiding inside the liver.

It then emerges from the liver at a different stage in its life cycle and infects red blood cells, where it starts reproducing.

Difficulty

The human immune system struggles to build up resistance to malaria and researchers have struggled in the laboratory.

There is still no approved vaccine against malaria. Large scale trials of the most advanced prototype – RTS,S – showed it halved the risk of getting malaria.

This study, published in Nature, looked at the moment the parasite infected a red blood cell.

They were looking for proteins on the surface of Plasmodium and red blood cells which were necessary for the parasite to identify its target and invade.

Others had been found before, but none were universally used.

The team at the Sanger Institute discovered that “basigin”, a receptor on the surface on red blood cells, and “PfRh5”, a protein on the parasite, were crucial.

In all strains of Plasmodium falciparum tested so far, interrupting the link protected the blood cells from attack.

One of the researchers, Dr Julian Rayner, said: “We were able to completely block invasion using multiple different methods, using antibodies targeting this interaction we could stop all invasion of red blood cells.

“It seems to be essential for invasion.”

The plan is to develop a vaccine which will prime the immune system to attack PfRh5 on the parasite

Fellow researcher Dr Gavin Wright said a vaccine would have great potential as the target was so essential.

“As a starting point for developing a vaccine you couldn’t hope for better,” he said.

Prof Adrian Hill, director of the Jenner Institute at Oxford University, said that after 25 years studying malaria he was “surprised” and “intrigued” by the findings.

He said textbooks and academic research suggested that if you blocked one pathway into the red blood cells, the parasite would choose another.

He added: “It remains to be seen how easy it will be to translate into a vaccine, but [for blood stage vaccines] PfRh5 is now at the top of the list.

“Vaccine candidates will come. If I had to bet, I’d say you’d get some partial efficacy from it.”

Share

Daily Aspirin Blocks Bowel Cancer

By James Gallagher Health reporter, BBC News

A daily dose of aspirin should be given to people at high risk of bowel cancer, say scientists.

Two pills a day for two years reduced the incidence of bowel cancer by 63% in a group of 861 at-risk patients, a study reported in The Lancet said.

Newcastle University’s Prof Sir John Burn, who led the study, said the evidence “seems overwhelmingly strong”.

Other experts said the findings added to a growing body of proof that aspirin could be used in the fight on cancer.

The study was conducted on 861 patients with Lynch syndrome, which affects one in every 1,000 people.

They struggle to detect and repair damaged DNA which means they are more likely to develop a range of cancers including those of the bowel, womb and stomach.

‘Good deal’

When looking at all patients in the trial, those in the group given 600 milligrams of aspirin every day developed 19 tumours compared to 34 tumours in the other “control” group, a reduction of 44%.

When the researchers looked at just those patients who took the medication for at least two years the reduction was 63%.

There was also an effect on other cancers linked to Lynch syndrome, which fell by half in the treatment group.

Prof Sir John Burn, from Newcastle University, said there were 30,000 adults in the UK with Lynch syndrome.

If all were given the treatment he said it would prevent 10,000 cancers over 30 years and he speculated that this could possibly prevent 1,000 deaths from the disease.

However, there would also be side effects.

“If we can prevent 10,000 cancers in return for 1,000 ulcers and 100 strokes, in most people’s minds that’s a good deal,” he said.

“People who’ve got a clear family history of, particularly, bowel cancer should seriously consider adding low dose aspirin to their routine and particularly those people who’ve got a genetic predisposition.”

Aspirin is already well known to reduce the risk of heart attack and stroke in high risk patients.

Other studies over the past two decades have suggested the pain killer reduced cancer risk, but this was the first randomised control trial, specifically for aspirin in cancer, to prove it.

In 2010, a study suggested patients given aspirin had a 25% lower risk of death during that trial.

Prof Peter Rothwell, from Oxford University, who conducted that study said the latest research “certainly helps to build a consistent picture, all pointing in the same direction that there is a link with cancer”.

Cancer Research UK’s Prof Chris Paraskeva said: “This adds to the growing body of evidence showing the importance of aspirin, and aspirin-like drugs, in the fight against cancer.”

‘Balanced argument’

One of the questions asked by the research into aspirin was whether healthy people with no family risks should take the drug.

The lower the risk of heart attack or cancer, the lower the benefit of taking aspirin, yet there are still potentially deadly side effects.

Sir John said that it was a “finely balanced argument” and that he decided the risks were worth it for him.

“I think where we’re headed for is people that are in their 50s and 60s would look very seriously at adding a low dose aspirin to their daily routine because it’s giving protection against cancer, heart attack and stroke.

“But if they do that they’ve got to have their eyes wide open. They will increase their risk of ulcers and gastrointestinal bleeds and very rarely they will have a stroke caused by the aspirin.”

Share

In Ghana, Stigma Stymies Breast Cancer Prevention

Inter Press Service (IPS), by Paul Carlucci and Henrietta Abayie

(Ghana) — Mary Mingle thought she had a boil on her breast, so she bought some medication and tried to treat it at home. Two months later, bothered by persistent pain, she went to the doctor. There were eleven lumps in her breasts. She had first stage cancer, and her breasts, along with her uterus, would have to be removed.

“The doctor encouraged me,” she says. “The earlier I got them removed, the better. Otherwise, I would lose my life.”

Now, years after her surgery, only five people in her personal life know about her double mastectomy: her three children, her sister, and her husband. She’s been carrying her secret for about 20 years, hiding it from her extended family with a padded bra because she is afraid she will be stigmatised. She also hides it from her church, for the same reason.

“I don’t want them to be aware,” she says, her voice a tiny whisper.

Health officials in Ghana say breast cancer is a growing problem compounded by untrained medical practitioners, a lack of equipment, and unhealthy, sometimes fatal, cultural beliefs.

Historically, breast cancer has received scant attention in this West African country. International donors and institutions have been focused on communicable diseases like malaria and HIV/AIDS. Despite the fact that, according to Ghana Health Services (GHS), non-communicable diseases are the leading causes of death.

“It’s only now that attention is being drawn to it,” says Dr. Kofi Nyarko, head of the GHS cancer control programme.

There aren’t any solid statistics yet. In the capital of Accra, the Korle Bu Teaching Hospital, one of two full service cancer facilities in the country, is building an in-hospital registry of cases. In Kumasi, the country’s second biggest city in Ashanti Region, Komfo Anokye Teaching Hospital is also working on a database.

According to Dr. Verne Vanderpuye, a clinical oncologist at Korle Bu, the hospital gets about 3,000 breast cancer referrals a year.

“The main problem is that people don’t come early,” she says. “In an untreated case, when it’s moved beyond the breast, the average lifespan is one-and-a-half to two years. It will move from the breast, to the lymphs, to the lungs, to the liver, to the bones, and to the brain.”

Nyarko says the hospitals have gathered enough information for officials to know that breast cancer is becoming more prevalent, and its victims are younger and younger.

“It’s no longer a disease for the old,” he adds.

About three years ago, a focus on non-communicable disease began to take shape. In 2008, in collaboration with the World Health Organization (WHO), the Ministry of Health set up a national Cancer Steering Committee. The following year, Nyarko became the government’s cancer chief.

Working with WHO, GHS has identified cost effective treatment and detection strategies. Radiology equipment is scarce in Ghana – there are 10 mammogram machines in the whole country, six of which are in private institutions – so there will be a focus on clinical examinations, with mammograms for follow ups. It is a strategy that will require training.

“You need human resources,” Nyarko says. “You need infrastructure. You need certain equipment in place. You need all these things and money for training. The fact that you are a doctor or you are a nurse does not mean you can examine someone and say, ‘You are free (of cancer).’ You need to be trained.”

Nyarko expects a comprehensive national strategy will be launched by the end of the year. In addition to increased clinical examinations, the government would also like to build a full service hospital in Tamale, the biggest city in Ghana’s relatively undeveloped Northern Region.

There is also a big emphasis on prevention and awareness, with a series of posters and leaflets produced in partnership with the Geneva-based Union for International Cancer Control. Aside from promoting exercise and fresh food diets, the campaign is also meant to chip away at Ghana’s cultural oppression of breast cancer victims.

“People think that cancer is a call to death, but we are telling them that cancer can be cured,” Nyarko says. “We are aware that awareness is very low, even amongst the social elite. So we are working on that.”

It is not uncommon for victims to be shunned by their husbands or families. And in a country where women do a good deal of work, both around the house and in markets, husbands are reluctant to lose their wives to months of treatment.

Furthermore, chemotherapy is not covered by health insurance and can cost almost 2,000 dollars in just two weeks.

According to the World Bank, Ghana’s 24 million people live on an average of 1,283 dollars a year. The Jubilee oil find in the country’s Western Region is expected to help push GDP growth to 13.4 per cent in 2011, but there is no guarantee that will influence the average annual income.

“There’s also the fact that you could lose your breast,” says Vanderpuye. “We have a polygamous society, whether we like it or not. They might say you are not a whole woman.”

Like many African countries, Ghana is hugely religious. Many pastors tell their flocks that cancer is a spiritual illness, and that the answer is prayer, not surgery. As a result, some women do not go to the hospital until the tumours have spread. And then they die.

“They say the surgery kills, but they wait so long that the cancer spreads, so it appears surgery kills,” says Gladys Boateng, a breast cancer survivor and the founder of Reach for Recovery.

Civil society groups like Reach for Recovery also play a role in spreading awareness. Formed after Boateng survived her own bout with breast cancer, the group has reached 3,000 sufferers in the past eight years. Survivors give back to the group, visiting women in hospitals and helping with screening missions in remote or rural areas.

But even advocates keep secrets. Boateng will not discuss her husband’s reaction to her ordeal. She just offers a tight smile and declines comment. Nyarko, who has been watching international dollars lean heavily toward infectious diseases, is predicting a continued sea change in donor awareness. He is ready – all he needs are resources.

“It’s just now that there’s an emphasis on non-communicable diseases,” he stresses. “You know the right thing to do. You know the right thing to say. But you do not have the resources.”

Share

Link Between Mobile Phones and Brain Cancer Rejected

By Nick Triggle Health correspondent, BBC News

Further research has been published suggesting there is no link between mobile phones and brain cancer.

The risk mobiles present has been much debated over the past 20 years as use of the phones has soared.

The latest study led by the Institute of Cancer Epidemiology in Denmark looked at more than 350,000 people with mobile phones over an 18-year period.

Researchers concluded users were at no greater risk than anyone else of developing brain cancer.

The findings, published on the British Medical Journal website, come after a series of studies have come to similar conclusions.

‘Reassuring’

But there has also been some research casting doubt on mobile phone safety, prompting the World Health Organization to warn that they could still be carcinogenic.

In doing so, the WHO put mobile phones in the same category as coffee, meaning a link could not be ruled out but could not be proved either.

The Department of Health continue to advise that anyone under the age of 16 should use mobile phones only for essential purposes and keep all calls short.

Continue reading the main story

“Start Quote

These results are the strongest evidence yet that using a mobile phone does not seem to increase the risk of cancers of the brain or central nervous system in adults”

Hazel Nunn Cancer Research UK

The Danish study, which built on previous research that has already been published by carrying out a longer follow-up, found there was no significant difference in rates of brain or central nervous system cancers among those who had mobiles and those that did not.

Of the 358,403 mobile phone owners looked at, 356 gliomas (a type of brain cancer) and 846 cancers of the central nervous system were seen – both in line with incidence rates among those who did not own a mobile.

Even among those who had had mobiles the longest – 13 years or more – the risk was no higher, the researchers concluded.

But they still said mobile phone use warranted continued follow up to ensure cancers were not developing over the longer term, and to see what the effect was in children.

Hazel Nunn, head of evidence and health information at Cancer Research UK, said: “These results are the strongest evidence yet that using a mobile phone does not seem to increase the risk of cancers of the brain or central nervous system in adults.”

Prof Anders Ahlbom, from Sweden’s Karolinska Institute, praised the way the study was conducted, adding the findings were “reassuring”.

Prof David Spiegelhalter, an expert specialising in the understanding of risk who is based at the University of Cambridge, said: “The mobile phone records only go up to 1995 and so the comparison is mainly between early and late adopters, but the lack of any effect on brain tumours is still very important evidence.”

And Prof Malcolm Sperrin, director of medical physics at Royal Berkshire Hospital, said: “The findings clearly reveal that there is no additional overall risk of developing a cancer in the brain although there does seem to be some minor, and not statistically significant, variations in the type of cancer.”

But the researchers themselves do accept there were some limitations to the study, including the exclusion of “corporate subscriptions”, thereby excluding people who used their phones for business purposes, who could be among the heaviest users

Share

Malaria Vaccine: Now A Possibility

GlaxoSmithKline research head Moncef Slaoui explains how change of focus to cellular immunity was key to breakthrough

Moncef Slaoui was on holiday with his family when he heard the results of the first small trial, involving African infants, of the malaria vaccine he helped invent. It was a day he would never forget.

“It was 9 August 2004,” he said. “I’m on vacation with my kids, driving between Chicago and Indianapolis and my phone rings and it’s the team calling from Mozambique. I had to stop for at least an hour. I couldn’t drive any more. That was a big, big moment.”

The vaccine had been classed as around 55-60% effective. It was the first sign that Slaoui, now chair of R&D at GlaxoSmithKline, and his colleagues, were going to be successful in cutting the terrible toll of malaria in Africa. Halving the 200m cases a year would save lives and prevent a huge amount of harm.

It had been a long haul. Slaoui had joined the Belgian lab of what was to become GlaxoSmithKline 23 years ago with a background in immunology. “I brought a fresh perspective in what was then modern immunology,” he said. Some of his new colleagues had started work on a malaria vaccine but “it was more or less stalled conceptually”.

No one then had managed to make a vaccine against a parasite infection. Many in the scientific community thought it impossible. “We heard that a lot. There were many controversial discussions on whether we would be able to achieve success,” said Slaoui.

But his ideas drove the effort in a new and successful direction.

Scientists had been attempting to kill off the parasites injected by malarial mosquitoes as soon as they entered the bloodstream. But any vaccine attempting that has only minutes to work because the parasites quickly go to the liver, where the next stage of their life cycle occurs. After five days there is a burst of new parasites in to the blood cells and that is when the child falls ill.

Slaoui suggested using cellular immunity. “Rather than using antibodies that can kill bacteria or a parasite, we used T-cells that recognise [a] cell is not normal because it is infected by a parasite. It opened the opportunity to find the parasite where it [hid] in the liver and kill it there.”

It was easy to say, but hard to do. They needed to find the right adjuvant, a substance that would stimulate the immune system’s T-cells to mount a response against the malaria parasites.

It was in 1996, eight years after Slaoui joined the vaccine effort, that they became sure they were on the right track – during experiments in conjunction with the Walter Reed army medical centre in Washington DC.

Slaoui said: “It was the first demonstration of the proof of concept that we were able to make a vaccine that killed the parasite in the blood and also in the liver.”

The approach used would later be employed in GSK’s pandemic flu and cervical cancer vaccines, which would make money. Slaoui said GSK would not have dropped the malaria vaccine programme, which was solely for the benefit of people too poor to pay, but that the proftable spin-offs undoubtedly helped.

He said: “GSK Biologicals’ leadership was always totally committed to continue the work on the malaria vaccine for two equally good reasons. The malaria vaccine was a great vehicle to advance our platform of adjuvants for many other vaccines, [ones] that were more able to give us a return. But secondly there was truly a commitment to public health in general and our responsibility to society to make vaccines for those who would most benefit, even when they could not afford it.”

This was a stronger motivation in the vaccine community than in the pharmaceutical industry. He added: “Vaccines are associated with public health and the developing world and babies that you save from major infections, and therefore the idealistic motivation is very strong.”

It remained the case, he said. “Yesterday in Seattle [when the results were published] I was with some of the first core-team members – we all started together. It was very emotional.

Share

IQ Can Change in Teenage YearsY

The mental ability of teenagers can improve or decline on a far greater scale than previously thought, according to new research.

Until now the assumption has been that intellectual capacity, as measured by IQ, stays quite static during life.

But tests conducted on teenagers at an average age of 14 and then repeated when their average age was nearly 18 found improvements – and deterioration.

The findings are published in the journal Nature.

They have implications for how pupils are assessed, and the age at which decisions about their futures are made.

This study involved 19 boys and 14 girls, all undergoing a combination of brain scans and verbal and non-verbal IQ tests in 2004 and then in 2008.

The results show that a change in verbal IQ was found in 39% of the teenagers, with 21% showing a change in “performance IQ” – a test of spatial reasoning.

The findings are seen to have greater validity because for the first time the variations in IQ correlated with changes in two particular areas of the teenagers’ brains.

An increase in verbal IQ corresponded with a growth in the density of part of the left motor cortex – a region activated during speech.

And an increase in non-verbal IQ correlated with a rise in the density of the anterior cerebellum – an area associated with movements of the hand.

The work was led by Professor Cathy Price of the Wellcome Trust Centre for Neuroimaging at University College London and is published in the journal Nature.

The paper suggests that the results could be “encouraging to those whose intellectual potential may improve and… a warning that early achievers may not maintain their potential”.

Professor Price said: “We have a tendency to assess children and determine the course of their education relatively early in life.

“But here we have shown that their intelligence is likely to be still developing.

“We have to be careful not to write off poorer performers at an early age when in fact their IQ may improve significantly given a few more years.”

The research did not seek to understand the causes of the changes.

One explanation is that teenagers mature at relatively different ages – with “early” and “late” developers – while relative standards in education may play a part too.

One of the participants, Sebastian Friston, now aged 23, recorded a marked increase in IQ between the two tests – from average to one of the highest categories.

Educated in the state sector, he told me he had struggled in his early years, needing remedial maths tuition, but is now planning a doctorate in computer engineering.

“I think the change came in school I started doing subjects that really interested me, that I was engaged in, then I found it easier and far more interesting.”

The research was funded by the Wellcome Trust, one of many projects supported under its programme of Understanding the Brain.

Future work may focus on how adaptable the brain may be beyond teenage years, and the implications for tackling mental diseases and other neurological conditions.

By David Shukman Environment & science correspondent, BBC News

Share

GlaxoSmithKline Malaria Vaccine Tests Show Hopeful Results

ATLANTA — The quest for the world’s first malaria vaccine appears to have taken a big step: A study in Africa shows experimental shots cut the risk of disease in young children by half.

The initial results from a final stage of vaccine testing were released Tuesday, and the vaccine’s developers called it a milestone in helping to tame one of the world’s most devastating killers.

However, the vaccine won’t be available for at least three years, as crucial further testing must be completed to see how well it works in infants and how long protection lasts. Then the vaccine must be reviewed by government agencies in Europe and in individual African countries.

“We still have a way to go,” Tsiri Agbenyega, lead researcher for the African study, said in a conference call with reporters.

The early results show the vaccine is only about 50 percent effective, significantly lower than the protection seen in more common vaccines. But some experts said it’s a vast improvement over the current situation, and could still save hundreds of thousands of lives.

Globally, malaria kills nearly a million people annually. More than 90 percent of them live in Africa, and most are young children and pregnant women.

Scientists have been trying for decades to develop a malaria vaccine and the one tested – developed by GlaxoSmithKline – is furthest along. Without a vaccine, efforts have concentrated on malaria drugs and other ways to prevent infection such as mosquito bed netting and insecticides.

The new vaccine targets a malaria parasite found in sub-Saharan Africa. Malaria spreads through mosquitoes, which bite people and flush malaria parasites into the bloodstream. The parasites cause bouts of high fever and can end in fatal organ failure.

In the United States, malaria has been eradicated since the early 1950s. Only about 1,500 cases are diagnosed in the U.S. each year, most of them travelers or immigrants from South Asia, sub-Saharan Africa or other places where malaria commonly spreads.

The new study – still under way – began in 2009 and involves more than 15,000 children in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania.

The results focus on about 6,000 children ages 5 to 17 months. A year after three doses, the vaccinated children had about half as many cases of malaria as a group that didn’t get the vaccine.

Meanwhile, experts are waiting for results from research in a younger group – infants ages 6 to 12 weeks. That’s the age when children in sub-Saharan Africa are vaccinated against other diseases. Earlier vaccination also affords earlier protection.

Although there are an array of vaccines against viruses and bacteria, there has never been an effective vaccine against a parasite, which is a more complicated organism. Adding to the complexity is there are five species of malaria parasites – the new vaccine is designed specifically to protect against the deadliest one, which is common in sub-Saharan Africa.

GlaxoSmithKline paid for the study along with the PATH Malaria Vaccine Initiative, a program funded by the Bill & Melinda Gates Foundation. The results were released Tuesday at a malaria conference in Seattle and published by the New England Journal of Medicine.

___

Share